Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Retained Earnings: 2010-2025

Historic Retained Earnings for Arrowhead Pharmaceuticals (ARWR) over the last 15 years, with Sep 2025 value amounting to -$1.6 billion.

  • Arrowhead Pharmaceuticals' Retained Earnings fell 0.10% to -$1.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.6 billion, marking a year-over-year decrease of 0.10%. This contributed to the annual value of -$1.6 billion for FY2025, which is 0.10% down from last year.
  • Per Arrowhead Pharmaceuticals' latest filing, its Retained Earnings stood at -$1.6 billion for Q3 2025, which was down 1.48% from -$1.6 billion recorded in Q2 2025.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Retained Earnings peaked at -$551.4 million during Q1 2021, and registered a low of -$1.8 billion during Q4 2024.
  • In the last 3 years, Arrowhead Pharmaceuticals' Retained Earnings had a median value of -$1.4 billion in 2025 and averaged -$1.3 billion.
  • Data for Arrowhead Pharmaceuticals' Retained Earnings shows a maximum YoY crashed of 58.78% (in 2024) over the last 5 years.
  • Quarterly analysis of 5 years shows Arrowhead Pharmaceuticals' Retained Earnings stood at -$707.6 million in 2021, then fell by 21.84% to -$862.1 million in 2022, then tumbled by 34.43% to -$1.2 billion in 2023, then crashed by 55.20% to -$1.8 billion in 2024, then fell by 0.10% to -$1.6 billion in 2025.
  • Its last three reported values are -$1.6 billion in Q3 2025, -$1.6 billion for Q2 2025, and -$1.4 billion during Q1 2025.